Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for hematuria in IgA nephropathy (prospective real-world study)
ChiCTR2600124141Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in IgA nephropathy (IgAN), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Urine occult blood, Urine red blood cell count and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600124141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124141.